Dr Hamilton on the Potential of RLY-2608 in PI3K-Mutated Breast Cancer

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research, Sarah Cannon Research Institute, discusses the potential of the PI3K inhibitor RLY-2608 in PI3K-mutated breast cancer.

Related Keywords

,Sarah Cannon Research Institute ,Gynecologic Cancer Research ,Erikap Hamilton ,D ,Pi3k Mutated Breast Cancer ,Rly 2608 ,Pi3k Inhibitor ,